Form SC 13D - General Statement of Acquisition of Beneficial Ownership:
SEC Accession No. 0000947871-21-000256
Filing Date
2021-02-23
Accepted
2021-02-22 18:31:23
Documents
2
Group Members
ORBIMED ADVISORS III LTDORBIMED ASIA GP III, L.P.ORBIMED CAPITAL GP VII LLC

Document Format Files

Seq Description Document Type Size
1 SCHEDULE 13D ss192859_sc13g.htm SC 13D 130006
2 JOINT FILING AGREEMENT ss192859_ex9901.htm EX-99.1 7564
  Complete submission text file 0000947871-21-000256.txt   139191
Mailing Address 601 LEXINGTON AVENUE 54TH FLOOR NEW YORK NY 10022
Business Address 601 LEXINGTON AVENUE 54TH FLOOR NEW YORK NY 10022 (212) 739-6400
ORBIMED ADVISORS LLC (Filed by) CIK: 0001055951 (see all company filings)

EIN.: 133976876 | State of Incorp.: DE
Type: SC 13D

Mailing Address 1065 EAST HILLSDALE BLVD., SUITE 100 FOSTER CITY CA 94404
Business Address 1065 EAST HILLSDALE BLVD., SUITE 100 FOSTER CITY CA 94404 650-525-5535 EXT.101
Terns Pharmaceuticals, Inc. (Subject) CIK: 0001831363 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13D | Act: 34 | File No.: 005-92116 | Film No.: 21662104
SIC: 2834 Pharmaceutical Preparations